8-K: Iridex Reports Mixed Q2 2024 Results with Revenue Growth and Strategic Review

Iridex Corporation announced its second quarter 2024 financial results, showing revenue growth and a recent $3.4 million capital raise, while also continuing its strategic review process.

Summary

• Iridex Corporation reported a total revenue of $12.6 million for the second quarter of 2024, a 7% increase compared to the first quarter of 2024, but relatively flat compared to the same period last year.
• Retina product revenue reached $7.3 million, showing an 8% sequential growth and a 6% year-over-year increase.
• The Cyclo G6 product family generated $3.3 million in revenue, with a 13% sequential growth in revenue, driven by a 12% increase in probe sales.
• The company sold 15,100 Cyclo G6 probes in Q2 2024, compared to 13,300 in Q1 2024, but slightly less than the 15,500 in Q2 2023.
• Iridex sold 28 Cyclo G6 Glaucoma Laser Systems in Q2 2024, up from 22 in Q1 2024, but down from 41 in Q2 2023.
• Gross profit was $5.1 million with a 40.7% gross margin, down from $5.4 million and 41.7% in the same period last year.
• Operating expenses decreased to $7.8 million, a $0.5 million reduction compared to the same period last year due to cost reduction initiatives.
• The net loss for the quarter was $2.7 million, or $0.16 per share, compared to a net loss of $2.8 million, or $0.17 per share, in the same period last year.
• Cash and cash equivalents were approximately $4.1 million as of June 29, 2024, with an additional $3.4 million raised through a convertible note offering on August 7, 2024.
• The company is actively pursuing a strategic review process and aims to complete a transaction this fiscal year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to sequential revenue growth and a successful capital raise, but tempered by flat year-over-year revenue, a decrease in gross margin, and ongoing strategic review uncertainty.

Positives

• Iridex achieved sequential revenue growth of 7% in Q2 2024 compared to Q1 2024.
• Retina product revenue showed strong growth, increasing by 8% sequentially and 6% year-over-year.
• Cyclo G6 product revenue increased by 13% sequentially, driven by a 12% increase in probe sales.
• The company successfully raised $3.4 million through a convertible note offering, strengthening its balance sheet.
• Operating expenses decreased by $0.5 million compared to the same period last year due to cost reduction initiatives.
• The net loss per share improved slightly from $0.17 to $0.16 year-over-year.

Negatives

• Total revenue was relatively flat compared to the same period last year, with a slight decrease from $12.9 million to $12.6 million.
• Gross profit decreased to $5.1 million with a 40.7% gross margin, down from $5.4 million and 41.7% in the same period last year.
• Cyclo G6 system sales decreased compared to the same period last year, impacted by ongoing capital purchasing constraints.
• Other revenue decreased by $0.3 million due to a reduction in royalty revenue from expired patent licensing.
• Cash and cash equivalents decreased by $1.3 million during the quarter.

Risks

• The company is facing ongoing capital purchasing constraints, which are impacting system sales.
• The reduction in royalty revenue from expired patent licensing is negatively impacting other revenue.
• The company's cash position decreased by $1.3 million during the quarter.
• The company is undergoing a strategic review process, which introduces uncertainty about its future direction.
• The company's gross margin decreased due to shifts in product mix.

Future Outlook

Iridex is prioritizing its strategic review process and aims to complete a transaction this fiscal year. The company expects to continue its growth recovery and maintain solid liquidity through further expense reductions and the recent convertible note funding.

Management Comments

• David Bruce, CEO of Iridex, stated that the second quarter results demonstrate stabilization of the business.
• He noted solid year-over-year growth in the Retina business and a 14% increase in glaucoma probe units over the first quarter.
• He mentioned a firmer capital environment with more extended-cycle equipment sales, but noted that cycles generally remain elongated.
• He highlighted that stabilized procedure reimbursement in the U.S. supported sequential improvements in glaucoma probe shipments.
• He reiterated the company's focus on its strategic review process and the goal to reach a transaction this fiscal year.

Industry Context

Iridex operates in the competitive medical device industry, specifically in the ophthalmology market. The company's performance is influenced by factors such as capital equipment purchasing cycles, reimbursement rates, and technological advancements. The company's focus on glaucoma and retinal treatments aligns with the growing prevalence of these conditions globally. The strategic review process suggests potential consolidation or acquisition activity in the sector.

Comparison to Industry Standards

• Iridex's revenue growth of 7% sequentially is a positive sign, but the flat year-over-year revenue indicates challenges in a competitive market. Companies like Lumenis and Ellex, which also operate in the ophthalmic laser market, have shown varying growth rates depending on their product mix and market focus.
• The decrease in gross margin from 41.7% to 40.7% suggests potential pricing pressures or shifts in product mix. Companies with strong brand recognition and premium products often maintain higher gross margins.
• The company's net loss of $2.7 million is not uncommon for companies in the medical device sector, especially those investing in R&D and sales expansion. However, consistent profitability is a key metric for long-term sustainability.
• The $3.4 million capital raise through a convertible note is a common strategy for companies seeking to fund operations and growth. However, the terms of the note, including potential dilution, need to be considered.

Stakeholder Impact

• Shareholders may be impacted by the strategic review process and potential transaction.
• Employees may be affected by cost reduction initiatives.
• Customers may experience changes in product availability or support due to the strategic review.
• Creditors may be impacted by the company's financial performance and debt obligations.

Next Steps

• Iridex will continue to pursue its strategic review process.
• The company will focus on completing a transaction this fiscal year.
• Iridex will continue to implement cost reduction initiatives.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

Iridex, financial results, medical devices, ophthalmology, laser systems, glaucoma, retina, Cyclo G6, revenue, net loss, strategic review, convertible note